Table 5.
Fixed and random-effects meta-analysis of the haplotypic association between disease outcome and the Thr92Ala-DIO2 polymorphism according to 3 inheritance models: dominant, overdominant and recessive
| Dominant model | Overdominant | Recessive | ||||||
|---|---|---|---|---|---|---|---|---|
| (Thr/Thr vs Thr/Ala + Ala/Ala) | (Thr/Ala vs Thr/Thr + Ala/Ala) | (Ala/Ala vs Thr/Ala + Thr/Thr) | ||||||
| Author, year | N | Major endpoint | P value | OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) |
| 1. Beltrao, 2021 | 220 | COVID-19 death | .1 | 1.83 (0.90-3.71) | .05 | 0.49 (0.24-1.00) | .6 | 1.38 (0.48-3.98) |
| 2. Taroza, 2020 | 168 | Depression after AIS | .3 | 2.20 (0.47-10.2) | .4 | 0.72 (0.36-1.43) | .6 | 1.21 (0.61-2.40) |
| 3. Kazukauskiene, 2020 | 283 | Cardiac-related death in ICU | .1 | 2.52 (0.77-8.23) | .3 | 0.54 (0.16-1.75) | .6 | 0.42 (0.02-7.29) |
| 4. Taroza, 2019 | 248 | AIS severity | .4 | 1.53 (0.52-4.49) | .04 | 0.58 (0.35-0.98) | .1 | 1.54 (0.92-2.57) |
| 5. Grineva, 2009 | 143 | LVH with Graves’s disease | .007 | 3.06 (1.36-6.90) | .02 | 0.36 (0.15-0.87) | .4 | 0.49 (0.10-2.34) |
| Metanalysis total (Fixed) | 1062 | .0003 | 2.18 (1.43-3.3) | .0002 | 0.54 (0.40-0.75) | .20 | 1.27 (0.88-1.83) | |
| Metanalysis total (Random) | 1062 | .0004 | 2.17 (1.41-3.3) | .0002 | 0.55 (0.40-0.75) | .17 | 1.30 (0.90-1.88) | |
| Heterogeneity analysis | Tau2 = 0.00; chi2 = 1.37, | Tau2 = 0.00; chi2 = 1.57, | Tau2 =0 .00; chi2 = 2.57, | |||||
| P = .85; I2 = 0% | P = 0.81; I2 = 0% | P = .63; I2 = 0% | ||||||
| Number of studies with P ≤ .05 | 1 studies | 3 studies | 0 studies | |||||
| Advantage (n)/Disadvantage (n) | 0/1 | 3/0 | 0/0 | |||||
Abbreviations: AIS, acute ischemic stroke; ICU, intensive care unit; LVH, left ventricular hypertrophy.